Fibro-indices versus liver stiffness for prediction of significant fibrosis in hepatitis B virus-infected Egyptian patients; a single-center experience. (3rd March 2020)
- Record Type:
- Journal Article
- Title:
- Fibro-indices versus liver stiffness for prediction of significant fibrosis in hepatitis B virus-infected Egyptian patients; a single-center experience. (3rd March 2020)
- Main Title:
- Fibro-indices versus liver stiffness for prediction of significant fibrosis in hepatitis B virus-infected Egyptian patients; a single-center experience
- Authors:
- Said, Mohamed
Eletreby, Rasha
Omar, Heba
Dabees, Hossam
Abdelghafour, Reem
El-Serafy, Magdy
Doss, Wahid - Abstract:
- ABSTRACT: Background : Liver fibrosis assessment is a key factor for disease management in hepatitis B virus (HBV). Several serum biomarkers have been introduced for noninvasive fibrosis assessment. This study aims to evaluate the validity of simple noninvasive indices, namely Fibrosis-4 score (FIB4), aspartate aminotransferase (AST) to Platelet Ratio Index (APRI), Goteborg University Cirrhosis Index (GUCI), and fibrosis index in evaluation of liver fibrosis in chronic HBV. Methods : 226 patients with chronic HBV genotype D were included. FIB4, APRI, GUCI, and fibrosis index were performed. Receiver operating characteristic (ROC) curves were used to predict ≥F2 fibrosis. Results : The mean age of patients was 39.00 years and 72.27% of patients were treatment naïve. Patients with ≥F2 hepatic fibrosis had significantly higher FIB-4 (1.58 ± 1.46 vs. 1.15 ± 1.09), APRI (0.68 ± 0.71 vs. 0.43 ± 0.37), GUCI score (0.75 ± 0.94 vs. 0.42 ± 0.29) and Fibrosis index (2.18 ± 0.84 vs. 1.84 ± 0.69). All studied indices were able to diagnose ≥F2 fibrosis. APRI had the highest area under the ROC (AUROC) of 0.67. Predictivity of all indices was higher in on-treatment vs naive patients. Conclusion : FIB4, APRI, and GUCI scores are acceptable, noninvasive, and cheap simple indices that can be helpful on treatment follow-up of fibrosis regression in the setting of low socioeconomic conditions compared to the relatively expensive fibroscan modality.
- Is Part Of:
- Expert review of gastroenterology & hepatology. Volume 14:Number 3(2020)
- Journal:
- Expert review of gastroenterology & hepatology
- Issue:
- Volume 14:Number 3(2020)
- Issue Display:
- Volume 14, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 14
- Issue:
- 3
- Issue Sort Value:
- 2020-0014-0003-0000
- Page Start:
- 221
- Page End:
- 227
- Publication Date:
- 2020-03-03
- Subjects:
- HBV -- noninvasive -- hepatic fibrosis
Gastroenterology -- Periodicals
Liver -- Diseases -- Periodicals
616.3 - Journal URLs:
- http://www.future-drugs.com/loi/egh ↗
https://www.tandfonline.com/toc/ierh20/current ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/17474124.2020.1723415 ↗
- Languages:
- English
- ISSNs:
- 1747-4124
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9830.067000
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 13649.xml